Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Bioverativ Therapeutics Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 5 examiners and 5 art units, creating a fully distributed examination profile. Counsel should treat the matters as separate prosecution tracks while maintaining consistent technical terminology and disclosure positions.
CHORBAJI, MONZER R is the busiest examiner, with 1 pending matter. The available record does not show concentration with one examiner, so portfolio oversight should emphasize coordination rather than reliance on a single examiner's practice. Each response should be tailored to its assigned art unit and the cited grounds.
Centralized review can still identify recurring issues in claim construction, written description, enablement, or prior-art treatment. Any common amendment should be tested against the individual prosecution histories before adoption, because the distributed assignments may produce different requirements for otherwise related biotechnology claims.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHORBAJI, MONZER R | 1 | 76.3% | +21.5% |
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| JACKSON III, WALTER | 1 | 50.0% | +0.0% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 47.2% | +63.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18903305 | ON-COLUMN VIRAL INACTIVATION METHODS | CHORBAJI, MONZER R | — |
| 18617239 | NUCLEIC ACIDS ENCODING FACTOR VIII POLYPEPTIDES WITH REDUCED IMMUNOGENICITY | YU, DELPHINUS DOU YI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17576561 | BACULOVIRUS EXPRESSION SYSTEM | LIPPOLIS, ALEXANDRA ROSE | 52d overdue |
| 18903305 | ON-COLUMN VIRAL INACTIVATION METHODS | CHORBAJI, MONZER R | — |
| Art Unit | Apps |
|---|---|
| 1799 | 1 |
| 1636 | 1 |
| 1638 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18903305 | ON-COLUMN VIRAL INACTIVATION METHODS | CHORBAJI, MONZER R | 1799 | §102§103 | Non-Final OA | — | Pending | Oct 01, 2024 |
| 18617239 | NUCLEIC ACIDS ENCODING FACTOR VIII POLYPEPTIDES WITH REDUCED IMMUNOGENICITY | YU, DELPHINUS DOU YI | 1636 | §102§103§112 | Non-Final OA | — | Pending | Mar 26, 2024 |
| 18440711 | BACULOVIRUS EXPRESSION SYSTEM | JACKSON III, WALTER | 1638 | §103 | Non-Final OA | — | Pending | Feb 13, 2024 |
| 17576561 | BACULOVIRUS EXPRESSION SYSTEM | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103DP | Non-Final OA | 52d overdue | Pending | Jan 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBioverativ Therapeutics Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Monzer R Chorbaji has the most, with 1 of Bioverativ Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
